XML 35 R7.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Cash flows from operating activities:    
Net loss $ (11,283,781) $ (10,680,366)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 129,653 125,885
Amortization of debt discount 7,981
Amortization of right-of-use assets 295,896 280,092
Accrued interest on convertible notes 166,019 164,611
Stock based compensation 151,505 184,465
Change in fair value of warrant liability (34,830) (821)
Change in fair value of convertible notes 3,630,100 1,250,000
Forgiveness of accounts payable (56,285)
Loss on disposal of property and equipment 41,417 7,923
Impairment of intangible assets and deferred patent costs 351,360
Changes in operating assets and liabilities:    
Accounts receivable 84,565 (21,953)
Prepaid expenses (288,124) (49,844)
Other assets (253) 694
Tax credits receivable (48,717) 103,645
Accounts payable and accrued expenses (68,684) 420,752
Income tax receivable 6,886 (15,024)
Operating lease liability (283,102) (268,509)
Contract liabilities (156,000) 141,000
Net cash used in operating activities (7,362,375) (8,349,469)
Cash flows from investing activities:    
Purchases of property and equipment (26,544) (33,101)
Proceeds from sale of property and equipment 4,250
Capitalization of deferred patent costs (214,152) (180,802)
Capitalization of licenses (65,510)
Capitalization of patent and trademark costs (77,563) (61,598)
Net cash used in investing activities (318,259) (336,761)
Cash flows from financing activities    
Proceeds from convertible notes, net of issuance costs 4,350,000
Payment of deferred offering costs (216,886)
Principal payments on finance leases (7,392)
Proceeds from initial public offering, net of transaction costs 5,991,359
Proceeds from exercise of stock options 1,510
Net cash provided by financing activities 5,983,967 4,134,624
Net change in cash and cash equivalents (1,696,667) (4,551,606)
Cash and cash equivalents at beginning of period 3,492,656 8,044,262
Cash and cash equivalents at end of period 1,795,989 3,492,656
Supplemental disclosure of non-cash investing and financing information:    
Obtaining a right-of-use asset in exchange for lease liability 1,418,502
Obtaining a right-of-use asset in exchange for financing lease liability 46,452
Conversion of note to common stock 9,495,072
Conversion of note to Series B Convertible Preferred Stock 1,124,759
Conversion of Series A, A-1, and B Convertible Preferred Stock to common stock $ 34,819,301